SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.

Five years after the World Health Organization declared a global pandemic, there has been progress — and backsliding in the ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

Research identifies how viral respiratory infection damages macrophages and suggests treatment with a pre-existing FDA approved drug.

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

SARS-CoV-2 has been evolving the ability to evade the immune system about twice as fast as the fastest-evolving flu virus. It averages more than a dozen significant changes every year.

Researchers have uncovered changes in the cellular response throughout lung damage caused by SARS-CoV-2—the virus behind ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...